Group 1 - The company plans to raise approximately HKD 23.33 billion by placing 35 million existing shares at a price of HKD 66.65 per share, with a net amount of about HKD 22.94 billion expected after expenses [1] - The placement price represents a discount of 9.5% to the closing price prior to the announcement and a 6.78% discount to the average price over the past five days [1] - This is the second equity financing since the company's IPO, with total fundraising now nearing HKD 40 billion, significantly higher than the initial IPO amount of HKD 5.49 billion [1] Group 2 - In 2024, the company achieved revenue of approximately HKD 55.39 billion, a year-on-year increase of about 57%, and a net profit of approximately HKD 20.62 billion, up 42% year-on-year [2] - The gross profit margin stands at 82.1%, with the main product line, 可复美, generating sales of HKD 45.42 billion, a 62.9% increase, and accounting for 82.0% of total revenue [2] - The company faces challenges such as low R&D investment, which was only HKD 1.06 billion (1.9% of revenue) in 2024, compared to competitors with significantly higher R&D expense ratios [2]
折价9%，巨子生物拟募资23亿港元